Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 2, 2024Open Access

Optical Genome Mapping improves detection and streamlines analysis of structural variants in myeloid neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

GRGordana RacaTST. SahooMIM. Anwar Iqbal

Discussion

Loading...

Member takes

Overview

Retrospective study demonstrates enhanced detection of structural variants via optical genome mapping in myeloid neoplasms, indicating a streamlined workflow for clinical cytogenetics.

Key Points

  • Evaluate the concordance, efficiency, and diagnostic capability of Optical Genome Mapping and VIA software for detecting structural variants in myeloid malignancies.
  • Retrospectively reviewed 56 datasets representing 10 unique myeloid neoplasm cases across multi-user evaluations by technologists and laboratory directors.
  • Evaluated structural variant detection and classification using Optical Genome Mapping (OGM) and the Variant Intelligence Applications (VIA) platform compared to standard-of-care cytogenetic methods.
  • Demonstrated 100% concordance between reviewers for four standard-of-care negative cases and unanimous Tier 1A reporting for five sentinel gene fusions.
  • Identified additional clinically relevant structural variants in five of the six positive cases that were not detected by standard-of-care testing.
  • Achieved a mean technologist review time of 30.7 minutes for complete variant analysis and initial tier determination using automated pre-classification.

Cite This Study

Raca et al. (2024) studied this question.

synapsesocial.com/papers/6aaccef44963efd150c0da74https://doi.org/10.1101/2024.01.02.24300691
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A framework for the clinical implementation of optical genome mapping in hematologic malignancies2024 · 56 citations
  2. 2Low-Pass Genome Sequencing2020 · 88 citations
  3. 3Technical laboratory standards for interpretation and reporting of acquired copy-number abnormalities and copy-neutral loss of heterozygosity in neoplastic disorders: a joint consensus recommendation from the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium (CGC)2019 · 84 citations
  4. 4Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers2021 · 304 citations
  5. 5High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance2022 · 89 citations